14-day Premium Trial Subscription Try For FreeTry Free
Date Action Amount Person Type
Dec 08, 2023 Sell 27 771 Tidmarsh George F Common Stock
Oct 16, 2023 Sell 1 845 Tidmarsh George F Common Stock
Oct 16, 2023 Sell 10 957 Tidmarsh George F Common Stock
Sep 28, 2023 Sell 1 429 Tidmarsh George F Common Stock
Sep 27, 2023 Buy 0 Chawla Lakhmir S
Sep 18, 2023 Sell 4 000 Tidmarsh George F Common Stock
Sep 15, 2023 Sell 9 500 Tidmarsh George F Common Stock
Sep 14, 2023 Sell 12 000 Tidmarsh George F Common Stock
Apr 18, 2023 Buy 25 000 Tidmarsh George F Common Stock
Apr 17, 2023 Buy 26 500 Tidmarsh George F Common Stock
Apr 14, 2023 Buy 6 356 Tidmarsh George F Stock Option (Right to Buy)
Apr 14, 2023 Buy 6 356 Roper Jess Stock Option (Right to Buy)
Apr 14, 2023 Buy 6 356 Labelle Curt H Stock Option (Right to Buy)
Apr 14, 2023 Buy 6 356 Carver Jennifer Stock Option (Right to Buy)
Feb 25, 2023 Buy 611 Zygmont Chester Stanley Iii Stock Option (Right to Buy)
Feb 25, 2023 Buy 2 542 Rolke James Stock Option (Right to Buy)
Dec 31, 2022 Buy 0 Axa Im Prime Impact Master Fund I Sca Sicav-raif
Feb 25, 2022 Buy 20 000 Tidmarsh George F Common Stock
Feb 09, 2022 Buy 30 000 Tidmarsh George F Common Stock
Feb 08, 2022 Buy 1 000 Tidmarsh George F Common Stock
Feb 07, 2022 Buy 42 100 Tidmarsh George F Common Stock
Feb 07, 2022 Buy 42 100 Tidmarsh George F Common Stock
Feb 04, 2022 Buy 7 900 Tidmarsh George F Common Stock
Feb 04, 2022 Buy 2 000 Tidmarsh George F Common Stock
Feb 04, 2022 Buy 7 900 Tidmarsh George F Common Stock
Jan 10, 2022 Buy 0 Zygmont Chester Stanley Iii Common Stock
Jan 10, 2022 Buy 0 Zygmont Chester Stanley Iii Common Stock
Jan 10, 2022 Buy 0 Zygmont Chester Stanley Iii Common Stock
Jan 10, 2022 Buy 15 588 Zygmont Chester Stanley Iii Restricted Stock Unit
Jan 10, 2022 Buy 0 Tidmarsh George F Common Stock
Jan 10, 2022 Buy 0 Tidmarsh George F Common Stock
Jan 10, 2022 Buy 21 422 Tidmarsh George F Restricted Stock Unit
Jan 10, 2022 Buy 21 422 Roper Jess Restricted Stock Unit
Jan 10, 2022 Buy 0 Rolke James Common Stock
Jan 10, 2022 Buy 0 Rolke James Common Stock
Jan 10, 2022 Buy 65 050 Rolke James Restricted Stock Unit
Jan 10, 2022 Buy 21 422 Labelle Curt H Restricted Stock Unit
Jan 10, 2022 Buy 0 Carver Jennifer Common Stock
Jan 10, 2022 Buy 21 422 Carver Jennifer Restricted Stock Unit
Jan 10, 2022 Sell 731 950 Feis Lawrence Common Stock
Oct 13, 2021 Buy 0 Feis Lawrence Common Stock
Sep 23, 2021 Sell 611 541 Glazer Capital, Llc Common stock, $0.001 par value per share
Sep 22, 2021 Sell 5 Glazer Capital, Llc Common stock, $0.001 par value per share
Sep 21, 2021 Sell 43 000 Glazer Capital, Llc Common stock, $0.001 par value per share
Mar 11, 2021 Buy 0 Carson William Howard Common Stock
Dec 30, 2020 Sell 192 962 Fitzpatrick Sean H Common Stock
Dec 30, 2020 Sell 192 962 Typaldos Andreas Common Stock
Nov 09, 2020 Sell 5 000 Glazer Capital, Llc Units
Oct 16, 2020 Buy 83 446 Fitzpatrick Sean H Redeemable Warrant
Oct 12, 2020 Sell 20 Glazer Capital, Llc Units
Oct 09, 2020 Sell 9 328 Glazer Capital, Llc Units
Oct 08, 2020 Buy 0 Glazer Capital, Llc Units
Oct 07, 2020 Buy 0 Typaldos Andreas Common Stock
Oct 07, 2020 Buy 3 150 000 Typaldos Andreas Redeemable Warrant
Oct 07, 2020 Buy 0 Fitzpatrick Sean H Common Stock
Oct 07, 2020 Buy 3 150 000 Fitzpatrick Sean H Redeemable Warrant
Oct 07, 2020 Buy 0 Nicholson Robert D Common Stock
Oct 07, 2020 Buy 0 Angelides Kimon Common Stock
Oct 07, 2020 Buy 0 Dobkin David Common Stock
Oct 07, 2020 Buy 0 Dennis Barry Common Stock
Oct 07, 2020 Buy 0 Hayes Anthony Common Stock
INSIDER POWER
-10.268
Last 61 transactions
Buy: 6 782 849 | Sell: 1 854 270 (Shares)

Based on the 61 latest insides trades, we have calculated the insider power to be negative at a ratio of -10.268.

In total, the insiders bought 6 782 849 and sold 1 854 270 REVB shares in the last 61 trades.

Click to get the best stock tips daily for free!

About Revelation Biosciences, Inc.

Revelation Biosciences. Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is a... REVB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT